RE: NicRio9924 Sep 2025 10:59
Expo "there are still alot of unanswered questions."
1. Why haven't the Directors been named on the ML yet?
Songwe Helium Ltd was registered as a company in Tanzania in June as a matter of public record. The company directors have to be listed on the filing documents (but not published like Companies House do in the UK). You could make a confidential request for that information for a fee if you want to, although it might not be granted.
2. Who are the three institutional investors by name?
3. Lorna stated in a previous interview, that the 3 II's would be named in good time and all would make sense? Why hasn't this been disclosed yet?
The deal is brokered by Marex and they would have a non disclosure agreement. They will be debt funds interested in monetising capital events. As the CEO said, it's up to them if they want to disclose their identity. I think it's unlikely. It's normal only to identify the broker in these arrangements. There are a handful of London-based funds that regularly participate in these structures. There are occasionally, high worth family/individual entities prepared to take high risk for a potential rerate opportunity. Then there are some proprietary trading outfits (potentially offshore) who specialise in convertible arbitrage with or without a shorting leg (relying on discounted entry and fast selling to monetise returns). Splitting between three entities reduces risk and makes the debt easier to place. The fact that it’s a Marex-arranged CLN, and not a conventional placing, points strongly toward small specialist funds or trading houses comfortable with high-risk AIM, not large institutions or mainstream fund managers.
4. Why has the FS still not been released to the public yet, what information is being held back and for what reasons.
It was never intended to be published in full, that was made clear. They said that numbers from the FS would come out in the CPR, which they have done. The CP clearly had access to a full array of modelling and development plans along with the test data, which they summarise clearly. What is not there is the cost return assumptions of course. It would be good to see those.